A huge thank you to Kerry Reynolds Mass General Cancer Center who gave an absolutely amazing lecture today on #irAEs at the The James #SSCBC Conference Series this am #IO #Rockstar #WomenInMedicine Hematology & Oncology Women Physicians Group—HOWPG 👏
Kerry Reynolds was the mastermind here. Honored to be a part of this community and part of these discussions! #irAEs are a critical part of the story in immunotherapy drug development, and it is where we need to spend MUCH more time and effort! Thanks to Burroughs Wellcome Fund & Project Data Sphere
📢Can ePRO symptom monitoring be used to monitor for #immunotherapy side-effects? (1/2)
🌟Check out our systematic review JCO Clinical Cancer Informatics!
👍feasible + acceptable
🔔More data needed re G3/4 irAEs, type/duration immunosuppresion
🧠we suggest content/features for future systems
Shedding new light on the dark side of cancer immunotherapy - mechanisms of IRAEs. Just out in Science Translational Medicine, grateful for support from UCLA Health and American Thyroid Association and my collaborators Trevor E Angell MD Maureen Su Lab wix.to/yPSqMbG
☣️ Rare but life-threatening irAEs can have a lasting impact on our patients.
#OncTwitter , how do you strike a balance between effectively obtaining IO consent & communicating potential serious irAEs to patients without undue distress? H. Jack West, MD Jarushka Naidoo Jill Feldman
In real-world #immunerelated adverse events associated with favourable outcomes in non-small cell #lungcancer > first-line chemo #immunotherapy regardless:
- irAE grade
- treatment discontinuation
+ irAES predictable ( #NLR , SII, NHS-Lung score)
Our #BTOG23 #LCSM #Spinnaker
Fantastic meeting, great minds at work and more collaborations and cohesive efforts in the future to come!
Team #irae23
Kerry Reynolds Pauline Funchain Yousuf Zafar, MD MHS Jarushka Naidoo Elad Sharon Tomas G. Neilan, MD, MPH Louis Muglia Project Data Sphere alexa meara Burroughs Wellcome Fund
#TumorBoardTuesday Tom Jayram Arnab Basu Sam S. Chang MD, MBA Vinay Mathew Thomas Simon Kim, MD, MPH Alex Alvaro Alya R. M. Shamsan Michael Staehler Omar Mian Katie Coleman Josie Garcia Lee Jones Ricardo Arteaga Ashish M. Kamat, MD, MBBS Uromigos AJangMD Ben Miron Christopher Sweeney, MBBS Tanya Jindal Nikita Tripathi Petros Grivas Paulo G Bergerot Sarah P. Psutka MD MS Shilpa Gupta Sumanta K. Pal, MD, FASCO Tom Powles Nazli Dizman Karine Tawagi MD Shuchi Gulati MD Todd M. Morgan, MD Brian Shuch, MD Rafee Talukder Ali Khaki Toni Choueiri, MD Tian Zhang, MD, MHS Neeraj Agarwal, MD, FASCO Sophia Kamran, MD Dena Battle Darcy Burbage, DNP, RN, AOCN Nishita Tripathi Pedro C Barata Renée Bultijnck Han Zhu Helena ullgren Ronald Witteles Andrew T. Nguyen Sarah Waliany, MD, MS Rohan Garje, MD 14/15 #TumorBoardTuesday
💫Recap💫
📍Platinum based doublet chemotherapy is SOC 1L UC
📍Response to 1L chemo may predict response to subsequent tx, including IO
📍Subsequent line opts include IO, ADCs, & 🎯agents
📍Always be suspicious for iRAEs & ☎️local multi-d specialists
🚨 We are very proud of our 🌟 fellow Rayli Pichardo MD whose work on #IRAEs was just published in Targeted Oncology
🔗link.springer.com/article/10.100…
Season 1: Episode 20 is out NOW! This is the future of irAEs. Join us Afreen Shariff, MD Tian Zhang, MD, MHS as we discuss germ-line variants in #irAE with experts Toni Choueiri, MD Sasha Gusev Dana-Farber.
Now on Apple | Spotify | Google podcasts
podcasts.apple.com/us/podcast/che…
Mike Glover #TumorBoardTuesday Tom Jayram Arnab Basu Sam S. Chang MD, MBA Vinay Mathew Thomas Simon Kim, MD, MPH Alex Alvaro Alya R. M. Shamsan Michael Staehler Omar Mian Katie Coleman Josie Garcia Lee Jones Ricardo Arteaga Ashish M. Kamat, MD, MBBS Uromigos AJangMD Ben Miron Christopher Sweeney, MBBS Tanya Jindal Nikita Tripathi Petros Grivas Paulo G Bergerot Sarah P. Psutka MD MS Shilpa Gupta Sumanta K. Pal, MD, FASCO Tom Powles Nazli Dizman Karine Tawagi MD Shuchi Gulati MD Todd M. Morgan, MD Brian Shuch, MD Ali Khaki Toni Choueiri, MD Tian Zhang, MD, MHS Neeraj Agarwal, MD, FASCO Sophia Kamran, MD Dena Battle Darcy Burbage, DNP, RN, AOCN Nishita Tripathi Pedro C Barata Renée Bultijnck Han Zhu Helena ullgren Ronald Witteles Andrew T. Nguyen Sarah Waliany, MD, MS Rohan Garje, MD Would be interesting to look at response to and outcomes to ICI in pts who develop grade >=3 IRAEs
Just curious, how did this pt end up doing? Is he on 3rd line txt?
My turn at CDEI: honored to be a panelist w an esteemed group on #endocrine related irAEs after #immunotherapy . W Michael T McDermott, Bryan Haugen, Jane Reusch & myself.
Key point: endocrine irAEs often permanent. Treat and continue immunotherapy. CU Endocrinology CU Department of Medicine
Narjust Florez, M.D. Shruti Patel, MD #TumorBoardTuesday Arthi Sridhar Aakash Desai, MD, MPH Eric K. Singhi, MD Fawzi Abu Rous, MD ALK+ International Lalsangzuala Chhakchhuak Samuel Kareff, MD, MPH Alya R. M. Shamsan Liza Vaezi Nathan A. Pennell MD, PhD, FASCO National Comprehensive Cancer Network (NCCN) gilberto lopes Dr. Estela Rodriguez Lecia Sequist, MD, MPH filippo masini Dr. Antonio Calles 🫁🚭 Dr Anne-Marie Baird Martín Lázaro Fredrik Thege Charles Williams, PhD Ana I. Velázquez Mañana, MD MSc (she/her/ella) Heather Wakelee Vishesh Khanna MD Surbhi Singhal Joel W. Neal, MD, PhD Eleanor Mishra Dr. Baluku Joseph Bruce Kirenga 𝑫𝒓 𝑺𝒊𝒗𝒂 𝑷𝒓𝒂𝒔𝒂𝒅 𝑲 American Lung Association Jose Pacheco Florez Lab (Previously Duma Lab) Jarushka Naidoo Those are terrible. Have also seen some bad polyarthritis that can be really challenging to treat. Good argument for lots of multi-disciplinary involvement in treating irAEs- rheum colleagues have been v helpful! #TumorBoardTuesday
So happy to announce our upcomming meeting the 24 Nov 2023 on #immunotherapy and irAEs. We are SO delighted to present Jarushka Naidoo, Marco Donia, Claus Feltoft Jakob Seidelin og Christina Ruhlmann as speakers for #youngoncologists in Denmark 💙 #dontmiss
